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ABSTRACT
Introduction: We report previously
unpublished, early pilot studies performed
with a brain-health food supplement
containing a proprietary blend of 100 mg
phosphatidylserine (PS) and 80 mg
phosphatidic acid (PA) produced from soy
lecithin.
Methods: Serum analysis after single PS?PA
ingestion was performed in healthy
volunteers. A 3-month double-blind, placebo-
controlled study assessed the influence of three
PS?PA capsules/day, (300 mg PS ? 240 mg PA/
day) or placebo on memory and mood in
functioning, non-depressive elderly people
with memory problems, using the Wechsler
Memory Scale and the List of Depressive
Symptoms. Furthermore, a 2-month
randomized, double-blind, placebo-controlled
trial assessed the effect of three PS?PA
capsules/day (300 mg PS ? 240 mg PA/day) or
placebo on daily functioning, mental health,
emotional state, and self-reported general
condition in patients with Alzheimer’s disease
(AD).
Results: Serum PS peaked 90 min after
ingestion, returning to baseline after 180 min.
In the elderly, PS?PA [per protocol (PP) n = 31],
unlike placebo (PP n = 26), significantly
improved memory and prevented ‘‘winter
blues’’ in a pre–post comparison. In the
patients with AD, daily functioning (i.e., 7
activities of daily living) under PS?PA (PP
n = 53) remained unchanged, but declined
from 5.62 to 4.90 under placebo (PP n = 39;
P = 0.035), with significant group difference
(P = 0.021). The PS?PA group had 3.8%
deterioration and 90.6% stability in daily
functioning, compared to 17.9% and 79.5%
under placebo, respectively (P = 0.066). Forty-
nine percent of the PS?PA patients reported an
improved general condition, compared
to 26.3% under placebo (P = 0.084).
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Approximately, 43% of the PS?PA patients, but
none under placebo, continued post-trial
supplementation (while double-blinded). No
negative side effects were observed.
Conclusion: PS is efficiently absorbed after oral
consumption. A positive influence of PS?PA on
memory, mood, and cognition was
demonstrated among elderly test subjects.
Short-term supplementation with PS?PA in
patients with AD showed a stabilizing effect
on daily functioning, emotional state and self-
reported general condition. The data encourage
long-term studies with PS?PA in AD patients
and other elderly with memory or cognition
problems.
Keywords: Alzheimer’s disease; Cognition;
Daily functioning; Dementia; Elderly; Memory;
MemreePlusTM; Mood; Phosphatidic acid; Soy
lecithin-derived phosphatidylserine
INTRODUCTION
Cognitive impairment, such as memory loss
(dementia), with increasing age is common and
distressing to both the aged individual and their
family [1–3]. Due to a gradual decline in
cognitive capacity, patients with dementia are
no longer able to continue their former regular
occupational and social activities. Functional
limitation restricts activities that are essential to
daily living, such as bathing, dressing, toileting,
and eating [4]. The physical and emotional
impact of dementia caregiving is estimated to
have resulted in healthcare costs of $9.1 billion
in the United States in 2012 [5].
A ‘‘normal’’, gradual, age-associated memory
impairment (AAMI), with a decline of memory
tasks by 50% or more over adulthood and aging,
affects everybody [6]. Superimposed on this
normal development, the majority of patients
with dementia suffer from either a degenerative
disease of the brain, mainly Alzheimer’s disease
(AD), or from multiple infarcts of the brain
(vascular dementia), or from a combination of
the two [6]. In a 65-year-old man, the remaining
lifetime risk of AD has been shown to be 6.3%,
and the risk developing any dementing illness
to be 10.9%; with the corresponding risks for a
65-year-old woman of 12% and 19%,
respectively [7].
The distress associated with memory
impairments, including AD, has ignited a
search for viable treatments, and there have
been various pharmacological or nutritional
approaches explored to counter dementia [8, 9].
Age-related cognitive deficits have been
linked to various mechanisms, including
cumulative oxidative stress and age-related
changes in cellular metabolism [10]. Many
age-related neurochemical changes can be
traced to structural and functional
alterations in neuronal membranes [11]. A
decline of phospholipids—particularly
phosphatidylserine (PS) in neuronal
membranes—has been associated with
memory impairment and deficits in mental
cognitive abilities [12, 13]. This has led to the
proposal that administration of endogenously
occurring phospholipids may prevent or reverse
age-related neurochemical deficits [14].
The phospholipids PS and phosphatidic acid
(PA) are found in the neuronal membrane in
high concentrations and are essential to its
functioning, acting as a biological detergent,
and keeping fatty substances soluble and cell
membranes flexible [15, 16]. PS was also found
to reduce oxidative stress in the brain [17], as
well as to stimulate neurotransmitter release
[18, 19] and to increase brain glucose
metabolism [20, 21]. Experiments with PS-
supplemented rodents have shown an
improvement in memory, learning capacity,
and other cognitive parameters [19, 22–25].
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Several human studies have shown the
efficacy of bovine brain-derived PS in patients
with dementia [26]. For example, AAMI subjects
were supplemented by three-month
administration of bovine brain-derived PS,
300 mg daily [27]. An improvement on a
number of neuropsychological tests was
observed in the PS-supplemented subjects
relative to those receiving placebo [27]. In a
12-week study with 149 AAMI patients, those
supplemented with a bovine brain-derived PS
formulation [100 mg PS three times daily (tid)]
improved, relative to placebo, in daily life
learning and memory tasks [28]. In another
6-month double-blind study, 494 cognitively
impaired elderly were supplemented with
300 mg bovine brain-derived PS daily (or
placebo), resulting in a significant
improvement in behavioral and cognitive
parameters in the supplementation group [29].
In a different study, placebo-controlled
supplementation of elderly with 100 mg soy-PS
six times daily (n = 41, PS-group) for 12 weeks
did not reveal any significant cognitive
improvements [30]. In contrast, a 12-week
pilot study with 30 elderly volunteers
suggested that soy lecithin-derived PS (100 mg
tid) may have favorable effects on cognitive
function in elderly with memory complaints
[31]. Also, a different pilot study with 18 AAMI
patients demonstrated significant positive
effects on cognition [32]. A double-blind,
randomized-controlled study investigating the
effects of soy lecithin-derived PS on the
cognitive functions of elderly Japanese subjects
with memory complaints demonstrated (unlike
placebo) significantly improved memory scores
in PS-treated groups compared to baseline [33].
In different studies, PS-containing preparations
were found to selectively dampen stress levels in
humans [34–36], improve learning and
perception parameters in children with
attention-deficit hyperactivity disorder [37,
38], and improve the calculation speed of
athletes [39].
Due to concerns regarding bovine
spongiform encephalopathy, the use of PS
(and PA) produced by enzymatic conversion of
soybean lecithin [40, 41] is considered a safer
alternative. Although PS from both sources can
be considered safe [42, 43], currently, from a
regulatory point of view, only the non-bovine
brain-derived PS is allowed as a dietary
supplement. The understanding of bovine
brain-derived PS limitation initiated
development of practical enzymatic
conversion of soybean lecithin to PS and PA.
The first company to commercially produce soy
lecithin-derived PS was Lipogen Ltd. (Haifa,
Israel) in 1991. The availability of soy lecithin-
derived PS further necessitated clinical testing
of the new soy lecithin-derived PS in
comparison to the old bovine brain-derived PS.
In the following, we describe pharmacokinetic
data for soy lecithin-derived PS. Furthermore, the
effect of dietary soy lecithin-derived PS?PA
supplementation was evaluated in one
uncontrolled and two placebo-controlled studies
with elderly people with memory impairment or
dementia, including AD (see Table 1 for an
overview of the studies). The studies reported
here were performed between 1992 and 1999 and
were, to our knowledge, the first performed with
plant-derived PS.
METHODS
Kinetic Analysis of Soy Lecithin-Derived
PS
Standard soft gelatine capsules containing soy
lecithin-derived PS and PA were supplied by
Lipogen Ltd. (Haifa, Israel). The healthy
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volunteers gave informed consent for
participating in this study. The study complied
with the Helsinki Declaration of 1996, however,
an ethics committee vote was omitted since it
was not mandatory at the time. After overnight
fasting, healthy volunteers each received 5
standard soft gelatine capsules containing soy
lecithin-derived PS and PA (100 mg PS ? 80 mg
PA/capsule) which were consumed at time 0.
Five milliliters of venous blood were drawn at
time 0 and every 30 until 180 min. The plasma
was separated immediately and an exhaustive
extraction of serum lipids was performed: 1 ml
of plasma was mixed with 9 ml of isopropanol
and then with 10 ml of chloroform. The
mixture was then centrifuged and the clear
and homogeneous lipid extract was collected. It
included approximately 100 lg/ml
phospholipids.
Analysis of the individual phospholipids was
carried out using two-dimensional thin-layer
chromatography with chloroform, methanol,
and ammonia (ratio 60:35:5, respectively) as
first running solvent. Second running solvent
was chloroform, acetic acid, acetone, and water
(ratio 60:30:5:5, respectively). Scraped-off PL
spots were processed for phosphorus analysis.
The ratio of the phosphorus in the PS spot over
the sum of phosphorus of all PL spots (defined
as PS/PL) was taken as the measure of PS level in
the plasma.
Study 1: Effect of PS1PA on Memory
and Mood in Functioning Elderly
A 3-month study, performed in 1992 among
elderly residents of three Israeli rural collective
communities (Kibbutzim Givat Brenner, Gat,
and Galon), assessed the effect of soy lecithin-
derived PS (100 mg) and PA (80 mg) tid on
memory performance. The trial complied with
the Declaration of Helsinki (1989 version);
however, an ethics committee vote was not
received and a trial registration was not
performed as this was not mandatory at the
time. Informed consent was obtained from all
patients for being included in the study.
Participants were included according to the
following criteria: Hebrew-speaking men and
women aged 60–80 years who reported some
memory problems in daily life; a score of at least
25 out of 30 on the Folstein Mini-Mental State
Examination (MMSE) [44] (i.e., non-demented);
a score of\17 on the List of Depressive Symptoms
(LDS) [45], indicating that the subject was not
depressed; not suffering from any active or recent
major disease; and not taking medication that
could influence memory. Recruitment was
accomplished in coordination with the kibbutz
health committees and clinics. The nature of the
study was explained to the elderly at special
meetings.
The primary outcome measure was a score
change in the Wechsler Memory Scale (WMS;
without age correction) score [46]. The test
examines memory, learning, association, and
information gathering as distinct from
intelligence [47]. The components of the test
are orientation, information, concentration
(counting backwards 20–1), saying alphabet
backwards, adding by 3’s up to 40, repeating
short stories, repeating numbers forward and
backward, learning word associations, and
visual memory.
As an additional outcome variable, mood
was tested using the LDS [45], which contains
22 items expressing negative affect and 12 items
with positive affect. The resulting score was also
used to exclude those with a score of\17 during
recruitment.
Baseline measures included demographic,
social, functioning, and health data, as well as
the total number of years of education. Health
variables included diseases and medication use.
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Participants were randomly assigned to either
receive placebo (500 mg lecithin) or 100 mg of
PS ? 80 mg PA mixed with lecithin tid for
3 months (L-Telect, Lipogen Ltd., Haifa, Israel;
similar to current MemreePlusTM, Lonza Ltd.,
Basel, Switzerland).
Study 2: Effect of PS1PA on Daily
Functioning and General Condition
in 96 Patients with AD
A 2-month study, performed in 1995, was
designed as a double-blind, randomized,
placebo-controlled trial. Patients with AD were
recruited from the Kaplan Medical Centre
(Rehovot, Israel), from kibbutzim near
Rehovot, and the Israel Association of
Alzheimer’s Disease. Study substances and
procedures, as well as the informed consent
form, complied with the Declaration of Helsinki
(1989 version); however, an ethics committee
vote was not received and a trial registration
was not performed, as this was not mandatory
at the time. All participants or surrogates had
signed a written informed consent prior to the
beginning of the trial.
Participants were included according to the
following criteria: aged 50–90 years; diagnosed
with definite-probable AD (Alzheimer’s Disease
and Related Disorders Association); history of
dementia [6 months; reported level of
functioning limitations or decline; no acute or
chronic dysfunction in a major organ system; no
endocrine disorder; no chronic renal or hepatic
failure; no multi-infarct dementia; no dementia
due to Parkinson’s, Pick, or Creutzfeldt–Jakob
disease; and no suspected reversible dementia.
Without wash-out of possible previous
medications, 56 patients (58.3%) were orally
supplemented with 100 mg of PS ? 80 mg PA
mixed with lecithin tid (L-Telect); 40 patients
(41.7%) received placebo (starch).
Baseline and 2-month examinations
included general self-reporting and scoring of
activities of daily living (7-ADL) items [daily
functioning index from 0 to 7 with a point for
each independent task (bathing, dressing,
grooming, toileting, feeding, transferring, and
walking; 0 points means a failure in all tasks)]
[48]. The mental status was assessed by Folstein
MMSE [44], while mood was assessed by a
simplified Tel-Aviv University Rosen Target
Detection (RTD) test [45]. One-month post-
trial, still double-blinded, accessible patients/
families were asked by telephone whether they
continued to use the product at their own
expense.
Statistical Analysis
Data analysis for both studies was done using
the SPSS statistical package (IBM Corporation,
Armonk, NY, USA). For Study 1, all P values
are two-tailed unless otherwise indicated. The
influence of the main variables was also
estimated by the Pearson chi-square test for
categorical data. Both stepwise linear
regression and multiple linear regression
were performed to estimate the joint effect
of the variables.
For Study 2, distribution of all variables
was analyzed for outliers. Selected pairs of
variables were tested for the presence of
incompatible combinations of values. The
comparability of groups was tested using
t test for continuous variables and cross-
tabulation chi-square for discrete variables.
Comparison of effects in two groups was
performed for each parameter separately
using the following methods: independent
samples t test for after–before difference;
analysis of variance in two groups with
‘‘after’’ values as an outcome and ‘‘before’’
values as a covariate.
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RESULTS
Kinetic Analysis of Soy Lecithin-Derived
PS
Serum analysis of eight overnight-fasted
healthy volunteers (aged 28–52 years) after
ingestion of soy lecithin-derived PS?PA was
performed to assess the PS kinetics. The serum
level of PS in relation to the level of total serum
phospholipids before the intake was in the
range of 1.8–2.2%, but it started increasing
30 min after ingestion, with a peak value
90 min after intake and returned to basal level
180 min after intake (Fig. 1). The soy lecithin-
derived PS?PA was well-tolerated, with no side
effects reported.
Study 1: Effect of PS1PA on Memory
and Mood in Functioning Elderly
Study Population
Out of a total of 414 kibbutz members aged
60–80 years, 102 (24.6%) elderly reported some
memory difficulties. After invoking the
inclusion criteria, a total of 72 subjects of both
sexes were included in the study, after they had
submitted a written consent (40 PS?PA, 32
placebo). These non-depressed elderly with
memory problems performed the following
tests at baseline and after 3 months of PS?PA
(n = 40) or placebo (n = 32) supplementation:
(a) the WMS examined memory, learning,
association, and information gathering;
(b) mood was tested using the LDS.
At the end of 3 months, 57 participants could
be retested (Fig. 2, randomization scheme;
Table 2, characteristics of study population).
Fifteen subjects could not be located or
dropped out due to death, non-compliance, or
surgery. There were no statistically significant
differences between the dropouts of the placebo
group and the study group in any dimension
examined. The characteristics of the placebo
and supplementation groups are shown in
Table 2. The groups were found to be
statistically comparable.
The WMS
Figure 3a shows that there was a significant test–
retest improvement in total WMS scores for
both the PS?PA group and the placebo group.
The changes were significant in both the
placebo group (P\0.013) and the PS?PA
group (P\0.005).
Although no significant differences were
found when comparing the scores between
groups, further subgroup analysis shows that
the initial WMS score had a significant effect on
the change in the WMS score (Fig. 3b). For those
with a low initial score (\69), there was
no significant difference between groups
(P\0.91). However, for those with a higher
initial WMS score ([68), those who received a
placebo actually experienced a small score
decrease after 3 months, whereas those who
received PS?PA experienced a significant score
increase; accordingly, there was a significant
difference between groups (P\0.03).
Fig. 1 Overall average proﬁle of serum PS relative to total
serum PL in eight healthy volunteers after single ingestion
of ﬁve capsules of soy lecithin-derived PS ? phosphatidic
acid. PL Phospholipids, PS phosphatidylserine
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Regression analysis indicates that there was a
significantly greater effect of PS?PA
supplementation on those with high initial
WMS scores than on those with low initial
WMS scores.
An analysis of the nine components that
constitute the WMS score was performed: in the
placebo group, a significant increase in the
WMS score was found in the total score only
(3.3%, P\0.03). However, in the PS?PA group,
there was a highly significant increase not only
in the total score (3.5%, P\0.001) but also in
the test’s components: information (2.2%,
P\0.04), visual memory (10.6%, P\0.01),
and memorizing numbers (7.0%, P\0.01).
Mood Changes: LDS
To assess mood changes after PS?PA
administration, the score on the LDS was
assessed before and after supplementation
(Fig. 3c). In a pre–post comparison, the results
show that the placebo group experienced a
significant increase in depressive symptoms
between baseline (late summer) and the
second time point (winter; P\0.001), whereas
the PS?PA group revealed no significant change
(P\0.4).
Study 2: Effect of PS1PA on Daily
Functioning and General Condition
in Patients with AD
Study Population
Sixty-one women (63.5%) and 35 men with a
mean age of 75.3 years and with AD
participated in a study testing the effects of
soy lecithin-derived PS?PA on memory and
mood; one subject of each group dropped
before supplementation started, and another
2 subjects from the PS?PA group dropped out
Fig. 2 Schematic overview of the two double-blinded,
placebo-controlled studies. Asterisks one subject of each
group dropped out between allocation to the study group
and start of supplementation. AD Alzheimer’s disease, ITT
intention to treat, PA phosphatidic acid, PS
phosphatidylserine, PP per protocol
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during supplementation (Fig. 2, randomization
scheme; Table 2, baseline characteristics of ITT
population).
At baseline, 29.8% of the participants had
mild dementia (based on MMSE score), 21.2%
were at the moderate stage, and 12.8% at the
severe stage. 36.2% were categorized as
borderline (31 of them scored 24–26 points),
with a clinical diagnosis of AD made. At study
onset, 30% of the participants reported
dizziness, 23% reported sleep disorders, and
20% reported constipation. The characteristics
of the two randomized groups suggested that
they were comparable.
The analyzed PP population was 39 people
taking placebo, and 53 people taking PS?PA.
7-ADL Functioning Index
A comparison of the assessments of the
7-ADLs functioning index (Table 3) revealed
no progression of the deterioration (stability)
in the PS?PA group, compared to a decline
in the control group: from 5.62 to 4.90
(P = 0.039). The statistical significance of
the difference between the groups by this
measurement increased from P = 0.433
before the supplementation to P = 0.021
afterwards.
A positive effect could also be found in
7-ADL functioning change patterns rates
(Table 3): 3.8% of deterioration (2 of 53) in the
PS?PA group compared to 17.9% (7 of 39) in
placebo, and 90.6% of stability (48 of 53) versus
79.5% (31 of 39) in the control group
(P = 0.066).
Mental State (Folstein MMSE)
Examination of mental state (Folstein MMSE)
change patterns revealed a slight and non-
significant improvement in both groups
(P = 0.872; Fig. 4a). Deterioration and stability
rates were slightly better in the PS?PA group.
However, it should be noted that 12 of 51
(23.5%) patients in the PS?PA group progressed
from abnormal (B23) initial scores to normal
(\23) after supplementation, compared to 4 of
35 (11.4%) in the control group.
RTD Scale
A change pattern comparison of the means of
the index of emotional state (RTD scale)
indicated minor but insignificant changes
Table 2 Study population of the placebo-controlled
studies




Mean age, years (±SD) 71.4 ± 6.2 70.8 ± 7.0
Duration of education, years
(±SD)
12.4 ± 3.0 11.4 ± 3.1
Male 8 (26%) 11 (42%)
Female 23 (74%) 15 (58%)
Concomitant medication 12 (39%) 13 (50%)
1–2 diseases 14 (45%) 10 (39%)
C3 diseases 5 (16%) 8 (31%)
Total 31 26




Aged 50–65 years 8 (14.5%) 6 (15.4%)
Aged 66–80 years 29 (52.7%) 17 (43.5%)
Aged 81–90 years 18 (32.7%) 16 (41.1%)
High education (C13 years) 14 (25.5%) 5 (12.8%)
Male 23 (41.8%) 11 (28.2%)
Female 32 (58.2%) 28 (71.8%)
0–1 diseases 23 (41.8%) 11 (28.2%)
C2 diseases 32 (58.2%) 28 (71.8%)
Total 55 39
Values are presented as n (%) unless otherwise stated
AD Alzheimer’s disease, ITT intention to treat, PA
phosphatidic acid, PS phosphatidylserine, PP per protocol
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(P = 0.156; Fig. 4b). However, trends could be
observed: comparing the PS?PA group with the
placebo group, there were higher rates of
stability (32.7% vs. 24.2%, respectively) and
improvement (44.9% vs. 33.3%, respectively).
Also, the deterioration was only approximately
half as severe with 22.4% vs. 42.4%,
respectively.
Self-Reported General Condition
The assessment of the self-reported general
condition showed that 49.0% of patients in
the PS?PA group reported an improvement in
their general condition compared to 26.3% in
placebo group (P = 0.084; Fig. 4c).
Post-Trial Consumption Rate
The behavioral indicator of post-trial
consumption rates revealed a large difference
between the groups: 42.9% of the patients in
the PS?PA group (6 of 14 assessed patients)
decided to continue the supplementation at
their own expense, in contrast to 0 of 11 in the
placebo group (P = 0.010).
Safety and Tolerability
Regarding tolerability, 88.2% of the patients in
PS?PA group and 91.1% of placebo group
reported having no side effects at all. The
remaining patients could not remember or had
various sensations, most of which they could not
relate directly to the supplementation.
Historical Prospective Study: Effect
of PS1PA on Cognitive Abilities of Patients
with AD, other Dementia, or Memory Loss
Historical prospective data of out-patients of
two medical centers in Israel were analyzed for
the effects of PS?PA on the cognitive abilities of
68 cognitively impaired elderly suffering from
AD (76.1%), other dementia (14.9%), or
memory loss (8.9%). Most of the patients had
a moderate degree of dementia. Mean
supplementation with the soy lecithin-derived
PS?PA was for 1.4 ± 1.8 years (range 2 months–
13 years). Either no change or an improvement
after 3–6 months as well as after 12 months of
PS?PA supplementation could be demonstrated
Fig. 3 WMS score results. Mean ± SEM and P values for
one-tailed t test are indicated. a Test score before and after
3 months of PS?PA supplementation. b Change in WMS
score after 3 months of PS?PA supplementation by
baseline level (T1). c Depressive symptoms score before
and after 3 months of PS?PA supplementation. LDS List
of Depressive Symptoms, PA phosphatidic acid, PS
phosphatidylserine, WMS Wechsler Memory Scale
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(see Fig. S1 in the electronic supplementary
material). A statistically significant positive
influence of PS?PA supplementation could be
recorded in most categories with patients
suffering from cognitive impairments.
DISCUSSION
PS is a structural PL found in neuronal
membrane and is essential to its functioning
[15, 16]. In various studies, PS (mostly derived
from bovine brain) was found to improve
cognitive ability and functioning in demented
patients (see ‘‘Introduction’’). However, the use
of PS from a vegetative source, free of risk of
encephalopathy, is considered advantageous,
and the presented human studies were, to the
best of our knowledge, the first to use plant-
derived PS.
The kinetic analysis in healthy volunteers
demonstrated that soy lecithin-derived PS is
absorbed and metabolized, with elevated serum
levels for at least 1.5 h after an oral dose.
In Study 1 on 72 non-demented, non-
depressed, functioning elderly with various
degrees of AAMI, the post-supplementation
memory testing scores in the PS?PA
supplementation group were significantly
higher than baseline, with a higher degree of
significance compared to the placebo group.
Furthermore, when pre- and post-
supplementation results of components of the
memory test were compared, none of the
placebo group’s changes were statistically
significant, whereas results for maintaining
information, visual memory, and memorizing
numbers improved with statistical significance
of P\0.05 within the PS?PA group. The non-
significant improvement trends observed in the
placebo group may be explained as a learning
(test–retest) effect, and/or with the 4–8% of PA
also contained within soy lecithin [49].
Comparing both groups, we found that
subjects who received PS?PA supplementation
and who had scored high on the initial WMS
showed more significant memory
improvements, whereas those who had scored
low did not. A probable explanation may be the
rather small size of the study, as well as its
relatively short duration. PS?PA was also
observed to have clear beneficial effects in
patients with dementia, especially if the
expected gradual cognitive deterioration is
taken into consideration:
In the placebo-controlled, randomized study
involving patients with AD (Study 2), a
statistically significant positive effect of PS?PA
was found on the 7-ADLs functioning index,
while a significantly more pronounced
deterioration was revealed in the placebo group.
Functioning is considered to be highly
important in geriatric practice, since it is
strongly associated with pathology, and is a
determinant of measurable outcomes, such as
morbidity, mortality, hospitalization, and costs,
as well as efficacy of interventions and
treatments. The association of functioning
Table 3 Comparison of 7-ADL functioning index (Study
2)
PS1PA Placebo P value
Before–after comparison
Baseline 6.23 ± 1.98 5.62 ± 2.42 0.433
After 2 months 6.23 ± 2.19 4.90 ± 3.00 0.021
Difference 0.00 ± 0.52 –0.72 ± 2.05 0.039
Change pattern analysis
Deterioration 3.8% 17.9%
Stability 90.6% 79.5% 0.066
Improvement 5.6% 2.6%
7-ADL 7 activities of daily living, PA phosphatidic acid, PS
phosphatidylserine
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with quality of life and need of care is well
established [50].
The MMSE has a rather low sensitivity to
minor changes [51]; accordingly, only slight
positive trends after the supplementation of
PS?PA could be observed after 2 months.
However, the positive trends of PS?PA
supplementation on change patterns of
functioning and self-reported general
condition are encouraging. Significance could
possibly not be reached due to the short study
duration and the limited sample size.
The data from Study 2 is complemented by
the historical prospective data from 68
cognitively impaired elderly dementia
patients—especially memory categories and
organization skills appeared to improve with
PS?PA in pre–post comparison.
The superiority of the PS?PA
supplementation can also be derived from
the fact that 6 out of 14 (42.9%) patients (or
their families) in the PS?PA supplementation
group of Study 2 (while still double-blinded)
decided to continue the supplementation at
their own expense after study termination,
compared to none in the placebo group.
Similarly, many of those patients with
dementia analyzed in a historical prospective
manner continued PS?PA supplementation at
their own expense for more than a year (data
not shown).
In addition to the positive influence on the
memory, the study on functioning elderly
reveals a positive effect of PS?PA on mood.
None of the participants in Study 1 had been
initially depressed, since high LDS scores were
excluded. Nevertheless, a worsening of mood
with time was observed within the placebo
group, which was not seen in the PS?PA
supplementation group. ‘‘Winter blues’’, also
known as seasonal affective disorder or
seasonal depression, is a universal
phenomenon in higher latitudes [52, 53].
Since this study started in late summer and
ended in winter, we suggest that soy lecithin-
derived PS?PA may be advantageous in
prevention of ‘‘winter blues’’ and depression.
Maggioni et al. [54] reported a positive effect of
PS on geriatric depression.
Fig. 4 Change patterns of mental state, emotional state,
and self-reported general condition. The percentage of
patients who experienced deterioration, no change, or
improvement after 2 months of PS?PA supplementation
(white bars) or placebo (black bars) is indicated. a Mental
state (Folstein Mini-Mental State Examination); P = 0.872.
b Index of emotional state (Rosen Target Detection scale);
P = 0.156. c Self-reported general condition; P = 0.084.
PA phosphatidic acid, PS phosphatidylserine
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These results go along with strong trends
from Study 2 on patients with AD. There were
nearly twice as many patients with emotional
decline in the placebo group compared to the
PS?PA supplementation group, with higher
rates of improvement in the PS?PA group.
Dementia and mood are highly related, and
sometimes dementia is accompanied by
depression, thus the effects of PS on mood
may be indirect effects due to the positive
impact on cognition and memory.
CONCLUSION
Altogether our results suggest that PS?PA can
support memory and cognitive function, which
is especially apparent in those who have
developed cognition deficiencies. Further
investigations should assess a larger sample for
a longer duration, so that the full and
prolonged effects of PS?PA on cognition,
memory, daily functioning, and mood in
elderly and patients with dementia can be
more thoroughly determined.
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